Human Cytomegalovirus and Epstein-Barr virus specific immunity
in patients with ulcerative colitis

J 2021

Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis

CICCOCIOPPO, R., C. MENGOLI, E. BETTI, G. COMOLLI, I. CASSANITI et. al.

Základní údaje

Originální název

Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis

Autoři

CICCOCIOPPO, R., C. MENGOLI, E. BETTI, G. COMOLLI, I. CASSANITI, A. PIRALLA, Peter KRUŽLIAK (703 Slovensko, garant, domácí), M. CAPRNDA, L. POZZI, G. R. CORAZZA, A. DI SABATINO a F. BALDANTI

Vydání

Clinical and Experimental Medicine, Milan, SPRINGER-VERLAG ITALIA SRL, 2021, 1591-8890

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.057

Kód RIV

RIV/00216224:14110/21:00122152

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s10238-021-00702-2

UT WoS

000633271600001

Klíčová slova anglicky

Adaptive immunity; Epstein-Barr virus; Human Cytomegalovirus; Therapy; Ulcerative colitis

Štítky

14110121, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 8. 2021 09:54, Mgr. Tereza Miškechová

Anotace

V originále

Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are endowed with the ability of establishing lifelong latency in human hosts and reactivating in immunocompromised subjects, including patients suffering from ulcerative colitis (UC). We, therefore, aimed to investigate virus-specific immunity in UC patients. A cohort of 24 UC patients (14 responders and 10 refractory to therapy) and 26 control subjects was prospectively enrolled to undergo virus-specific serology (by ELISA assay) and assessment of both CD4(+) and CD8(+) virus-specific T-cell response (by interferon-gamma enzyme-linked immunospotanalysis). In parallel, mucosal viral load was determined by quantitative real-time PCR and the values were correlated with both clinical and endoscopic indexes of activity. For statistics, the t-test, Mann-Withney test, Fisher's exact test and Spearman rank correlation test were applied; p < 0.05 was considered significant. EBV-specific CD4(+) and CD8(+) T-cell responses were significantly lower in UC patients compared to controls (p < 0.0001 and p = 0.0006, respectively), whereas no difference was found for HCMV-specific T-cell response. When dividing the UC group according to response to therapy, both responders and refractory UC patients showed a deficient EBV-specific CD4(+) T-cell response with respect to controls (p < 0.04 and p = 0.0003, respectively). Moreover, both EBV and HCMV mucosal loads were significantly higher in refractory UC than in responders and controls (p = 0.007 and 0.003; and p = 0.02 and 0.001, respectively), and correlated with activity indexes. Steroid therapy seemed the main risk factor for triggering EBV colitis. Finally, no cases of IgM positivity were found in the study population. An impaired EBV-specific immunity was clearly evident in UC patients, mostly in those refractory to therapy. The ELISPOT assay may serve as new tool for quantifying and monitoring virus-specific T-cell immunity in UC.

Citovat

CICCOCIOPPO, R., C. MENGOLI, E. BETTI, G. COMOLLI, I. CASSANITI, A. PIRALLA, Peter KRUŽLIAK, M. CAPRNDA, L. POZZI, G. R. CORAZZA, A. DI SABATINO a F. BALDANTI. Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. Clinical and Experimental Medicine. Milan: SPRINGER-VERLAG ITALIA SRL, 2021, roč. 21, č. 3, s. 379-388. ISSN 1591-8890. Dostupné z: https://dx.doi.org/10.1007/s10238-021-00702-2.

@article{1787482,
   author = {Ciccocioppo, R. and Mengoli, C. and Betti, E. and Comolli, G. and Cassaniti, I. and Piralla, A. and Kružliak, Peter and Caprnda, M. and Pozzi, L. and Corazza, G. R. and Di Sabatino, A. and Baldanti, F.},
   article_location = {Milan},
   article_number = {3},
   doi = {http://dx.doi.org/10.1007/s10238-021-00702-2},
   keywords = {Adaptive immunity; Epstein-Barr virus; Human Cytomegalovirus; Therapy; Ulcerative colitis},
   language = {eng},
   issn = {1591-8890},
   journal = {Clinical and Experimental Medicine},
   title = {Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis},
   url = {https://link.springer.com/article/10.1007%2Fs10238-021-00702-2},
   volume = {21},
   year = {2021}
}

TY  - JOUR
ID  - 1787482
AU  - Ciccocioppo, R. - Mengoli, C. - Betti, E. - Comolli, G. - Cassaniti, I. - Piralla, A. - Kružliak, Peter - Caprnda, M. - Pozzi, L. - Corazza, G. R. - Di Sabatino, A. - Baldanti, F.
PY  - 2021
TI  - Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis
JF  - Clinical and Experimental Medicine
VL  - 21
IS  - 3
SP  - 379-388
EP  - 379-388
PB  - SPRINGER-VERLAG ITALIA SRL
SN  - 15918890
KW  - Adaptive immunity
KW  - Epstein-Barr virus
KW  - Human Cytomegalovirus
KW  - Therapy
KW  - Ulcerative colitis
UR  - https://link.springer.com/article/10.1007%2Fs10238-021-00702-2
N2  - Human Cytomegalovirus (HCMV) and Epstein-Barr virus (EBV) are endowed with the ability of establishing lifelong latency in human hosts and reactivating in immunocompromised subjects, including patients suffering from ulcerative colitis (UC). We, therefore, aimed to investigate virus-specific immunity in UC patients. A cohort of 24 UC patients (14 responders and 10 refractory to therapy) and 26 control subjects was prospectively enrolled to undergo virus-specific serology (by ELISA assay) and assessment of both CD4(+) and CD8(+) virus-specific T-cell response (by interferon-gamma enzyme-linked immunospotanalysis). In parallel, mucosal viral load was determined by quantitative real-time PCR and the values were correlated with both clinical and endoscopic indexes of activity. For statistics, the t-test, Mann-Withney test, Fisher's exact test and Spearman rank correlation test were applied; p < 0.05 was considered significant. EBV-specific CD4(+) and CD8(+) T-cell responses were significantly lower in UC patients compared to controls (p < 0.0001 and p = 0.0006, respectively), whereas no difference was found for HCMV-specific T-cell response. When dividing the UC group according to response to therapy, both responders and refractory UC patients showed a deficient EBV-specific CD4(+) T-cell response with respect to controls (p < 0.04 and p = 0.0003, respectively). Moreover, both EBV and HCMV mucosal loads were significantly higher in refractory UC than in responders and controls (p = 0.007 and 0.003; and p = 0.02 and 0.001, respectively), and correlated with activity indexes. Steroid therapy seemed the main risk factor for triggering EBV colitis. Finally, no cases of IgM positivity were found in the study population. An impaired EBV-specific immunity was clearly evident in UC patients, mostly in those refractory to therapy. The ELISPOT assay may serve as new tool for quantifying and monitoring virus-specific T-cell immunity in UC.
ER  -

CICCOCIOPPO, R., C. MENGOLI, E. BETTI, G. COMOLLI, I. CASSANITI, A. PIRALLA, Peter KRUŽLIAK, M. CAPRNDA, L. POZZI, G. R. CORAZZA, A. DI SABATINO a F. BALDANTI. Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. \textit{Clinical and Experimental Medicine}. Milan: SPRINGER-VERLAG ITALIA SRL, 2021, roč.~21, č.~3, s.~379-388. ISSN~1591-8890. Dostupné z: https://dx.doi.org/10.1007/s10238-021-00702-2.

Podrobný výpis o publikaci